Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
923.34
-22.19 (-2.35%)
At close: Nov 19, 2026, 4:00 PM EST
925.00
+1.66 (0.18%)
After-hours: Nov 19, 2026, 7:58 PM EST
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,343 employees as of March 31, 2026. The number of employees increased by 185 or 1.22% compared to the same quarter last year. That makes Regeneron Pharmaceuticals the 2,360th largest employer in the world and 566th in the United States.
Employees
15,343
Change (1Y)
185
Growth (1Y)
1.22%
Revenue / Employee
$1,101,232
Profits / Employee
$313,980
Market Cap
92.66B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 15,343 | 185 | 1.22% |
| Dec 31, 2025 | 15,410 | 304 | 2.01% |
| Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
| Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
| Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
| Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
| Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
| Dec 31, 2019 | 8,100 | 700 | 9.46% |
| Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
| Dec 31, 2017 | 6,200 | 800 | 14.81% |
| Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
| Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
| Dec 31, 2014 | 2,925 | 585 | 25.00% |
| Dec 31, 2013 | 2,340 | 390 | 20.00% |
| Dec 31, 2012 | 1,950 | 246 | 14.44% |
| Dec 31, 2011 | 1,704 | 309 | 22.15% |
| Dec 31, 2010 | 1,395 | 366 | 35.57% |
| Dec 31, 2009 | 1,029 | 110 | 11.97% |
| Dec 31, 2008 | 919 | 237 | 34.75% |
| Dec 31, 2007 | 682 | 109 | 19.02% |
| Dec 31, 2006 | 573 | -15 | -2.55% |
| Dec 31, 2005 | 588 | -142 | -19.45% |
| Dec 31, 2004 | 730 | 86 | 13.35% |
| Dec 31, 2003 | 644 | -25 | -3.74% |
| Dec 31, 2002 | 669 | 94 | 16.35% |
| Dec 31, 2001 | 575 | 84 | 17.11% |
| Dec 31, 2000 | 491 | 54 | 12.36% |
| Dec 31, 1999 | 437 | 66 | 17.79% |
| Dec 31, 1998 | 371 | 101 | 37.41% |
| Dec 31, 1997 | 270 | 27 | 11.11% |
| Dec 31, 1996 | 243 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Vertex Pharmaceuticals | 6,400 |
| Moderna | 4,700 |
| Genmab | 3,244 |
| Incyte | 2,844 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
REGN News
- 18 hours ago - Regeneron announces new hematology portfolio data at ASH - TheFly
- 18 hours ago - Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH) - GlobeNewsWire
- 1 day ago - US FDA approves Regeneron's drug for generalized myasthenia gravis - Reuters
- 1 day ago - Regeneron’s Livsayis approved by FDA in gMG patients - TheFly
- 1 day ago - Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing - GlobeNewsWire
- 2 days ago - CytomX Therapeutics triggers $5M milestone payment in Regeneron collaboration - TheFly
- 2 days ago - Regeneron Pharmaceuticals Transcript: Jefferies Global Healthcare Conference - Transcripts
- 2 days ago - Regeneron reports EC approval for Libtayo alternative, flexible dosing schedule - TheFly